Company Filing History:
6 out of 6 
3 out of 3 Years Active: 2020-2024
Title: Wenzhi Tian: Innovator in Antibody Research
Introduction
Wenzhi Tian is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biopharmaceuticals. He holds a total of nine patents, showcasing his innovative work in antibody research and therapeutic applications.
Latest Patents
Among his latest patents is the development of antibodies binding CD24, which includes a detailed description of an antibody that specifically binds to CD24 or an antigen-binding portion thereof. This patent also covers a nucleic acid molecule encoding the antibody, an expression vector, and a host cell that comprises the nucleic acid molecule. Furthermore, it outlines methods for expressing the antibody and treating diseases associated with CD24 signaling using the antibody or its binding portion. Another notable patent involves recombinant fusion proteins targeting CD47 and CD24. This application provides a recombinant fusion protein that contains an anti-CD24 antibody or an antibody fragment linked to an extracellular Ig-like domain of a signal-regulatory protein (SIRP). The fusion protein is designed to bind to CD47, CD24, and FcR simultaneously, along with methods for producing the protein and treating diseases related to the overexpression of CD47 and/or CD24.
Career Highlights
Wenzhi Tian has worked with notable companies in the biopharmaceutical sector, including Immuneonco Biopharmaceuticals (Shanghai) Inc. and Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. His work in these organizations has contributed to advancements in therapeutic solutions targeting critical cellular pathways.
Collaborations
Wenzhi Tian has collaborated with esteemed colleagues such as Song Li and Dianze Chen, further enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Wenzhi Tian's innovative work in antibody research and his contributions to the biopharmaceutical industry highlight his role as a leading inventor in the field. His patents reflect a commitment to advancing medical science and improving treatment options for diseases associated with critical cellular signaling pathways.